Daratumumab Treatment Strategy for AL Amyloidosis
Author Information
Author(s): Z. Li, Guo Jinzhou, Chen Wencui, Zhao Liang, Ren Guisheng, Huang Xianghua
Primary Institution: National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
Hypothesis
Can a serum free light chain level-based and non-fixed cycle daratumumab treatment strategy improve outcomes for patients with light chain amyloidosis?
Conclusion
The study found that the serum free light chain level-based and non-fixed cycle daratumumab strategy is effective and safe for treating both newly diagnosed and relapsed/refractory AL amyloidosis.
Supporting Evidence
- The overall hematologic response rate was 94.3%.
- The median time to best hematologic response was 1 month.
- Cardiac and renal response rates were 39.3% and 60.3%, respectively.
- The 1-year overall survival estimate was 96.5%.
- The incidence of grade 3 or 4 adverse events was 21%.
Takeaway
Doctors used a new way to give a medicine called daratumumab to help people with a sickness called AL amyloidosis, and it worked really well for most of them.
Methodology
This retrospective study included 123 patients with AL amyloidosis who received daratumumab treatment adjusted based on serum free light chain levels.
Potential Biases
Selection bias may have occurred due to some cases being lost to follow-up.
Limitations
The study is limited by its retrospective nature, potential incomplete data reporting, and a relatively short follow-up period.
Participant Demographics
Median age of participants was 59 years, with 51.2% male and 86.2% being lambda-type.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website